Why Tigecycline Remains Commonly Prescribed Despite Being Off-Patent
Tigecycline, a glycylcycline antibiotic approved in 2005 for complicated skin/skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia, lost all its key U.S. patents by 2015 (e.g., composition-of-matter patent US 6,706,740 expired December 2014).[1] No generic versions have entered the U.S. market as of 2024, leaving Wyeth/Pfizer's Tygacil as the sole branded product.[1] Prescriptions persist—around 100,000 annually in recent years—due to its unique efficacy against multidrug-resistant (MDR) bacteria like Acinetobacter baumannii, carbapenem-resistant Enterobacteriaceae (CRE), and MDR Pseudomonas, where alternatives often fail.[2][3]
What Unique Role Does Tigecycline Fill in MDR Infections?
Tigecycline's broad-spectrum activity, including against extended-spectrum beta-lactamase (ESBL)-producers and anaerobes, makes it a go-to for severe hospital infections when first-line options like carbapenems or piperacillin-tazobactam are ineffective. Guidelines from IDSA and others recommend it for polymicrobial intra-abdominal infections or ventilator-associated pneumonia caused by resistant Gram-negatives.[4] Its bacteriostatic mechanism—binding 30S ribosomal subunit—bypasses common resistance pathways, unlike many beta-lactams.
Why Haven't Generics Launched Yet?
Despite patent expiry, no ANDAs for tigecycline generics have been FDA-approved. Challenges include complex manufacturing (fermentation-based synthesis with multiple stereocenters), stability issues in formulation, and high bioequivalence barriers due to its IV-only delivery and nonlinear pharmacokinetics.[1][5] Pfizer's 180-day exclusivity under Hatch-Waxman may have delayed early challengers, and no Paragraph IV litigation succeeded. DrugPatentWatch lists no pending generics, with the last pediatric exclusivity ending in 2016.[1]
How Does Pricing Compare to Alternatives?
Tygacil costs $1,500–$2,000 per full course (6–14 days), far above generics like vancomycin ($200–500) or meropenem ($500–1,000), yet hospitals prescribe it for resistant cases where failure risks outweigh expense—e.g., MDR Acinetobacter mortality exceeds 40% without effective therapy.[3][6] Off-patent status hasn't dropped prices without competition; some markets like India have generics at 20–30% of U.S. branded cost.
What Do Prescribers Say About Limitations and Risks?
Common concerns include higher mortality in ventilator-associated pneumonia (VAP) trials (OR 1.28), FDA black-box warnings for that indication, and side effects like nausea (26%), vomiting (18%), and elevated liver enzymes.[7] Prescribers still use it off-label for CRE bacteremia or osteomyelitis due to few alternatives; surveys show 60–70% of ID specialists rank it highly for MDR Gram-negatives despite risks.[8]
When Could Generics Finally Arrive?
FDA's 2023 GDUFA incentives target complex generics like tigecycline, with potential approvals by 2025–2027 if sponsors overcome CMC hurdles. No active ANDAs are public, but rising CRE cases (CDC urgent threat) may spur development.[1][9] Biosimilar-like pathways aren't applicable as it's a small-molecule drug.
[1]: DrugPatentWatch.com - Tigecycline Patents
[2]: CDC Antibiotic Resistance Threats Report, 2019
[3]: Clinical Infectious Diseases, 2017 (IDSA CRE guidelines)
[4]: IDSA Skin/Soft Tissue Guidelines, 2014
[5]: FDA Orange Book; no tigecycline generics listed
[6]: Wholesale Acquisition Cost data, IQVIA 2023
[7]: Tygacil Prescribing Information, Pfizer 2023
[8]: Open Forum Infectious Diseases survey, 2022
[9]: FDA GDUFA VI Priorities, 2023